<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02884544</url>
  </required_header>
  <id_info>
    <org_study_id>HLD100-103</org_study_id>
    <nct_id>NCT02884544</nct_id>
  </id_info>
  <brief_title>A Study of Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) in Children With ADHD</brief_title>
  <acronym>HLD100-103</acronym>
  <official_title>Phase II, Open-label, Dose-titration, Safety Study Designed to Determine the Evening Dose of a Novel Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) to Produce Optimal Clinical Effects in Children With ADHD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ironshore Pharmaceuticals and Development, Inc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ironshore Pharmaceuticals and Development, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The phase 2 study will evaluate the safety, tolerability and efficacy of HLD100 at steady&#xD;
      state (following up to 5 weeks of treatment) in children using an outpatient, single-center,&#xD;
      open-label, flexible dose-escalation study design.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This dose-escalation study will examine HLD100 in 24 subjects.&#xD;
&#xD;
      The subjects (n=24) will be tested with HLD100 in ascending doses from 10mg up to 40mg.&#xD;
&#xD;
      This study will be divided into several phases: Screening, Active Treatment and Follow-Up.&#xD;
      All visits have a 2 day window to allow for scheduling.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Actual">December 27, 2016</completion_date>
  <primary_completion_date type="Actual">December 18, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Escalation to determine optimal dosage for clinical effects</measure>
    <time_frame>6 weeks</time_frame>
    <description>Primary outcome is the determination of the dose achieving optimal clinical effect in a safe and tolerable manner</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety (AEs, ECG, laboratory parameters, physical examinations)</measure>
    <time_frame>48 hours</time_frame>
    <description>Safety endpoints include treatment-emergent adverse events (TEAEs), vital signs, electrocardiogram (ECG) parameters, physical examination, and the C-SSRS.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Attention-Deficit Hyperactivity Disorder (ADHD)</condition>
  <arm_group>
    <arm_group_label>HLD100 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HLD100 (dextroamphetamine sulfate) DR/ER capsules (10mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HLD100 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HLD100 (dextroamphetamine sulfate) DR/ER capsules (20mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HLD100 30mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HLD100 (dextroamphetamine sulfate) DR/ER capsules (30mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HLD100 40mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HLD100 (dextroamphetamine sulfate) DR/ER capsules (40mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HLD100</intervention_name>
    <description>Treatment</description>
    <arm_group_label>HLD100 10mg</arm_group_label>
    <arm_group_label>HLD100 20mg</arm_group_label>
    <arm_group_label>HLD100 30mg</arm_group_label>
    <arm_group_label>HLD100 40mg</arm_group_label>
    <other_name>Dextroamphetamine sulfate, delayed release/extended release</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must have a diagnosis of ADHD as defined by DSM-5 criteria with confirmation&#xD;
             using the Mini International Neuropsychiatric Interview for Children and Adolescents&#xD;
             (MINI-KID).&#xD;
&#xD;
          -  Subjects must demonstrate mild-to-moderate impairment of ADHD symptoms and function&#xD;
             per the following at screening (V1) and/or baseline (V2):&#xD;
&#xD;
               -  ADHD-RS-IV score at or above the 90th percentile normalized for sex and age in&#xD;
                  total score and ≥24 at Baseline;&#xD;
&#xD;
               -  CGI-S score ≥4;&#xD;
&#xD;
          -  Subject body weight must be ≥20 kg.&#xD;
&#xD;
          -  Subject must be considered clinically appropriate for treatment with amphetamine and&#xD;
             HLD100, including prior treatment experience with an amphetamine product, and ability&#xD;
             to swallow treatment capsules.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of, or current, medical condition or laboratory result which, in the opinion&#xD;
             of the investigator, unfavorably alters the risk-benefit of study participation, may&#xD;
             jeopardize subject safety, or may interfere with the satisfactory completion of the&#xD;
             study and study-related procedures.&#xD;
&#xD;
          -  Serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm&#xD;
             abnormalities, or other cardiac problems that may place the subject at increased&#xD;
             vulnerability to the sympathomimetic effects of a stimulant drug.&#xD;
&#xD;
          -  History of seizure disorder (except febrile seizures prior to age 5 and with last&#xD;
             occurrence at least 1 year prior to study participation), Tourette's disorder, or&#xD;
             intellectual disability of minor severity or greater (DSM-5 criteria).&#xD;
&#xD;
          -  History of psychosis, bipolar disorder, anorexia nervosa, bulimia, or suicide attempt.&#xD;
             Current depression, anxiety, conduct/behavior disorder, substance use disorder, or&#xD;
             other psychiatric condition which, in the investigator's opinion, may jeopardize&#xD;
             subject safety or may interfere with the satisfactory completion of the study and&#xD;
             study-related procedures.&#xD;
&#xD;
          -  Active suicidal ideation as evidenced by an ideation score of 2 or greater on the&#xD;
             C-SSRS.&#xD;
&#xD;
          -  History of severe allergic reaction or intolerance to amphetamine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann Childress, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Psychiatry &amp; Behavoural Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Psychiatry and Behavioral Medicine, Inc.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 28, 2016</study_first_submitted>
  <study_first_submitted_qc>August 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2016</study_first_posted>
  <disposition_first_submitted>September 7, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>September 7, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 12, 2018</disposition_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dextroamphetamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

